Targeting colony stimulating factor-1 receptor signalling to treat ectopic pregnancy.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
24 09 2020
Historique:
received: 15 04 2020
accepted: 07 09 2020
entrez: 25 9 2020
pubmed: 26 9 2020
medline: 22 12 2020
Statut: epublish

Résumé

1-2% of pregnancies are ectopic, the majority implanting in the Fallopian tube. A single, systemic dose of methotrexate, a DNA-synthesis (S phase) inhibitor, has been used since 1991 for outpatient treatment of women with stable EP. However, methotrexate has limited clinical and cost effectiveness, restricting its use to 25-30% of these women. There is an unmet need for better medical treatment for EP. Colony stimulating factor-1 (CSF-1) promotes placentation and creates a pro-inflammatory environment that is fundamental for the maintenance of a normal pregnancy. We hypothesised that CSF-1 is also involved in the placentation and maintenance of an EP. Herein, we demonstrate the immunolocalisation of the CSF-1 receptor (CSF-1R) as well as its ligand (CSF-1) in immortalised first trimester trophoblast cells. We show that a specific CSF-1R kinase inhibitor, GW2580, abolishes CSF-1 induced trophoblast cell proliferation and migration and can be cytotoxic. We then demonstrate the expression of CSF-1R and CSF-1 in the cytotrophoblast and syncytiotrophoblast within ectopic implantation sites from women with EP. Our data suggests that CSF-1 is involved in the survival and proliferation of trophoblast cells in EP. This suggests that pharmacological disruption of CSF-1/CSF-1R signaling axis could be the basis of a new therapeutic for EP.

Identifiants

pubmed: 32973322
doi: 10.1038/s41598-020-72785-y
pii: 10.1038/s41598-020-72785-y
pmc: PMC7519033
doi:

Substances chimiques

Macrophage Colony-Stimulating Factor 81627-83-0
Receptor, Macrophage Colony-Stimulating Factor EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15638

Subventions

Organisme : Chief Scientist Office
ID : CZB/4/513
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1100356
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 108766/Z/15/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0802808
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N022556/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N024524/1
Pays : United Kingdom
Organisme : Department of Health
ID : 14/150/03
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom

Références

Jurkovic, D. & Wilkinson, H. Diagnosis and management of ectopic pregnancy. BMJ 342, d3397. https://doi.org/10.1136/bmj.d3397 (2011).
doi: 10.1136/bmj.d3397 pubmed: 21665933
Taran, F. A. et al. The diagnosis and treatment of ectopic pregnancy. Dtsch. Arztebl. Int. 112, 693–703 (2015).
pubmed: 26554319 pmcid: 4643163
Shao, R. Understanding the mechanisms of human tubal ectopic pregnancies: new evidence from knockout mouse models. Hum. Reprod. 25, 584–587 (2010).
doi: 10.1093/humrep/dep438
Sendy, F. et al. Failure rate of single dose methotrexate in managment of ectopic pregnancy. Obstet. Gynecol. Int. 2015, 902426 (2015).
doi: 10.1155/2015/902426
Guvendag Guven, E. S. et al. Comparison of single and multiple dose methotrexate therapy for unruptured tubal ectopic pregnancy: a prospective randomized study. Acta Obstet. Gynecol. Scand. 89, 889–895 (2010).
doi: 10.3109/00016349.2010.486825
Horne, A. W. & Critchley, H. O. Mechanisms of disease: the endocrinology of ectopic pregnancy. Expert Rev. Mol. Med. 14, e7 (2012).
doi: 10.1017/erm.2011.2
Sivalingam, V. N., Duncan, W. C., Kirk, E., Shephard, L. A. & Horne, A. W. Diagnosis and management of ectopic pregnancy. J. Fam. Plann. Reprod. Health Care 37(4), 231–240 (2011).
doi: 10.1136/jfprhc-2011-0073
Ngwenya, S. Challenges in the surgical management of ectopic pregnancy in a low-resource setting: Mpilo Central Hospital Bulawayo Zimbabwe. Trop. Doct. 47, 316 (2017).
doi: 10.1177/0049475517700810
Agdi, M. & Tulandi, T. Surgical treatment of ectopic pregnancy. Best Pract. Res. Clin. Obstet. Gynaecol. 23, 519–527 (2009).
doi: 10.1016/j.bpobgyn.2008.12.009
Sowter, M. C., Farquhar, C. M., Petrie, K. J. & Gudex, G. A randomised trial comparing single dose systemic methotrexate and laparoscopic surgery for the treatment of unruptured tubal pregnancy. BJOG 108, 192–203 (2001).
pubmed: 11236120
Yang, Y. et al. M-CSF cooperating with NFkappaB induces macrophage transformation from M1 to M2 by upregulating c-Jun. Cancer Biol. Ther. 15, 99–107 (2014).
doi: 10.4161/cbt.26718
Hamilton, G. S., Lysiak, J. J., Watson, A. J. & Lala, P. K. Effects of colony stimulating factor-1 on human extravillous trophoblast growth and invasion. J. Endocrinol. 159, 69–77 (1998).
doi: 10.1677/joe.0.1590069
Rahmati, M. et al. Colony Stimulating Factors 1, 2, 3 and early pregnancy steps: from bench to bedside. J. Reprod. Immunol. 109, 1–6 (2015).
doi: 10.1016/j.jri.2015.01.005
von Rango, U. et al. Effects of trophoblast invasion on the distribution of leukocytes in uterine and tubal implantation sites. Fertil. Steril. 76, 116 (2001).
doi: 10.1016/S0015-0282(01)01859-3
Gerber, Y. N. et al. CSF1R inhibition reduces microglia proliferation, promotes tissue preservation and improves motor recovery after spinal cord injury. Front. Cell Neurosci. 12, 368 (2018).
doi: 10.3389/fncel.2018.00368
Leblond, A. L. et al. Systemic and cardiac depletion of M2 macrophage through CSF-1R signaling inhibition alters cardiac function post myocardial infarction. PLoS ONE 10, e0137515 (2015).
doi: 10.1371/journal.pone.0137515
Moughon, D. L. et al. Macrophage blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant ascites in late-stage epithelial ovarian cancer. Cancer Res. 75, 4742–4752 (2015).
doi: 10.1158/0008-5472.CAN-14-3373
Olmos-Alonso, A. et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology. Brain 139, 891–907 (2016).
doi: 10.1093/brain/awv379
Arceci, R. J., Shanahan, F., Stanley, E. R. & Pollard, J. W. Temporal expression and location of colony-stimulating factor 1 (CSF-1) and its receptor in the female reproductive tract are consistent with CSF-1-regulated placental development. Proc. Natl. Acad. Sci. USA 86, 8818–8822 (1989).
doi: 10.1073/pnas.86.22.8818
Pollard, J. W. et al. Apparent role of the macrophage growth factor, CSF-1, in placental development. Nature 330, 484–486 (1987).
doi: 10.1038/330484a0
Athanassakis-Vassiliadis, I., Papamatheakis, J. & Vassiliadis, S. Specific CSF-1 binding on murine placental trophoblasts and macrophages serves as a link to placental growth. J. Recept. Res. 13, 739–751 (1993).
doi: 10.3109/10799899309073690
Chitu, V. & Stanley, E. R. Regulation of embryonic and postnatal development by the CSF-1 receptor. Curr. Top. Dev. Biol. 123, 229–275 (2017).
doi: 10.1016/bs.ctdb.2016.10.004
Katano, K. et al. Low serum M-CSF levels are associated with unexplained recurrent abortion. Am. J. Reprod. Immunol. 38, 1–5 (1997).
doi: 10.1111/j.1600-0897.1997.tb00268.x
Lindhard, A. et al. Biochemical evaluation of endometrial function at the time of implantation. Fertil. Steril. 78, 221–233 (2002).
doi: 10.1016/S0015-0282(02)03240-5
Conway, J. G. et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc. Natl. Acad. Sci. USA 102, 16078–16083 (2005).
doi: 10.1073/pnas.0502000102
Holmgaard, R. B., Zamarin, D., Lesokhin, A., Merghoub, T. & Wolchok, J. D. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine 6, 50–58 (2016).
doi: 10.1016/j.ebiom.2016.02.024
Zur, Y. et al. A dual-specific macrophage colony-stimulating factor antagonist of c-FMS and alphavbeta3 integrin for osteoporosis therapy. PLoS Biol. 16, e2002979 (2018).
doi: 10.1371/journal.pbio.2002979
Ahmad, S. F. et al. Pelvic chlamydial infection predisposes to ectopic pregnancy by upregulating integrin beta1 to promote embryo-tubal attachment. EBioMedicine 29, 159–165 (2018).
doi: 10.1016/j.ebiom.2018.02.020
Nilsson, U. W. et al. Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth. Obstet. Gynecol. 122, 737 (2013).
doi: 10.1097/AOG.0b013e3182a1ba56
Skibisz, M. M. et al. Combination gefitinib and methotrexate compared with methotrexate alone to treat ectopic pregnancy. Obstet. Gynecol. 122, 745 (2013).
doi: 10.1097/AOG.0b013e3182a14cfb
Straszewski-Charez, S. L. et al. The isolation and characterization of a novel telomerase immortalized first trimester trophoblast cell line, Swan 71. Placenta 30, 939 (2009).
doi: 10.1016/j.placenta.2009.08.007
Edwards, D. K. et al. CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. Blood 133, 588 (2018).
doi: 10.1182/blood-2018-03-838946
Dwyer, A. R., Ellies, L. G., Holme, A. L. & Pixley, F. J. A three-dimensional co-culture system to investigate macrophage-dependent tumor cell invasion. J. Biol. Methods 3, e49 (2016).
doi: 10.14440/jbm.2016.132
Peng, B. et al. Gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor are expressed at tubal ectopic pregnancy implantation sites. Fertil. Steril. 105, 1620 (2016).
doi: 10.1016/j.fertnstert.2016.02.003

Auteurs

S Furquan Ahmad (SF)

MRC Centre for Reproductive Health, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, EH16 4TJ, UK.

W Colin Duncan (WC)

MRC Centre for Reproductive Health, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, EH16 4TJ, UK.

Lisa L Campbell (LL)

MRC Centre for Reproductive Health, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, EH16 4TJ, UK.

Robyn E Beaty (RE)

Edinburgh Medical School, University of Edinburgh, Edinburgh, EH16 4SA, UK.

Magda Koscielniak (M)

MRC Centre for Reproductive Health, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, EH16 4TJ, UK.

Frances Collins (F)

Centre for Inflammation Research, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, EH16 4TJ, UK.

Philippa T K Saunders (PTK)

Centre for Inflammation Research, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, EH16 4TJ, UK.

Andrew W Horne (AW)

MRC Centre for Reproductive Health, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, EH16 4TJ, UK. andrew.horne@ed.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH